Biopreservation and Biobanking

Publisher: Mary Ann Liebert

Journal description

Current impact factor: 1.50

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2011 Impact Factor 1.294

Additional details

5-year impact 1.26
Cited half-life 1.80
Immediacy index 0.28
Eigenfactor 0.00
Article influence 0.34
ISSN 1947-5543
OCLC 313373688
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Mary Ann Liebert

  • Pre-print
    • Author cannot archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Author's final version or publisher's version/PDF
    • Publisher's version/PDF may be used
    • On author's personal website, institution's intranet, or institutional repository
    • Authors may deposit in funder's designated repository after 12 months
    • Set statement to accompany deposit (see policy)
    • Publisher copyright and source must be acknowledged
    • NIH authors will have their final paper, (post peer review, copy-editing and proof-reading) deposited in PubMed Central on their behalf
  • Classification
    ​ blue

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Genome-wide sequencing in glioma samples provides comprehensive insights into oncogenesis and malignant transformation. Several distinct biomarkers have been proven to have clinical significance and are being widely applied in routine clinical practice. Standard sample processing lays the foundation for successful molecular testing. In this study, we found intraoperative neuronavigation ensured higher tumor purity during sample collection, and an automated device helped improve DNA quality and increased yields. These two technologies are beneficial for glioma tissue bank construction and provide for accurate molecular testing during routine clinical practice.
    Biopreservation and Biobanking 02/2015; 13(1):31-36.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human tissue biorepositories have become key platforms for the acceleration of basic and translational biomedical research on cancer in China. The maintenance of sufficient amounts of tumor cells is critical for a wide variety of cancer studies. Ensuring the high quality of frozen stored tissue specimens is a crucial requirement. However, different tumor locations and various methods of tumor tissue removal can lead to variable numbers of tumor cells from banked tissue specimens. Thus, an effective method to assess the tumor cell content is essential for tissue samples in biobanks. In the present study, the mirror image method was used to evaluate the amount of tumor cells in stored tumor tissues of six common cancer types, including solid and hollow organ cancers. All tissues were stored in the Tianjin Medical University Cancer Institute and Hospital (TMUCIH). Histological assessment was performed by pathologists who conducted morphological diagnoses of tumor percentage on mirror image sections of frozen stored samples that were stained with hematoxylin and eosin (H&E). Results showed that the tumor percentage of solid organ cancers was higher than that of hollow organ cancers (χ(2)=17.11, p<0.0001). Among solid organ cancers, the highest tumor percentage was observed in renal tumor tissues, and likewise esophagus tumor tissues had the highest tumor content among hollow organ cancers (multiple tests, p<0.05). Three kinds of samples, which showed higher proportions of tumor content under 25%, were stomach, liver, and colorectal cancers, and the proportions were 15.0%, 10.9%, and 10.6%, respectively. Therefore, histological assessment based on the review of mirror-image H&E sections offers the most direct and objective judgment. The results can not only be applied to the tissue quality feedback process of biobanks, but also guide a wide variety of scientific studies.
    Biopreservation and Biobanking 02/2015; 13(1):25-30.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Peripheral blood leukocytes (PBLs) are the main source of DNA in blood samples. A common protocol is to store buffy coat specimens for future DNA isolation, and such samples may remain in frozen storage for years. However, the currently available methods to maintain buffy coat specimens can be optimized for better quality and cost efficiency. Study Design and Methods: Seventeen donors (aged 24-34 years) were enrolled in this study. Initially, five centrifugal speeds were chosen to examine the distribution of PBLs in the cell layer; the buffy coat was then harvested to evaluate the cell quantity and viability after storing at 4°C for various times. Finally, the buffy coat was isolated, snap frozen, and kept at -80°C for 1 hour, 1 week, or 4 weeks until the DNA was extracted. Agarose gel electrophoresis and multiplex PCR were used to verify DNA integrity and amplifiability. Results: There was a linear positive correlation between the amount of fresh PBLs and the DNA yield. At least 70% of PBLs were collected in the uppermost 40% of the cellular material when the centrifugal force was over 800 g compared to 400 g. Storing blood at 4°C for no more than 24 hours did not have an effect on the amount of PBLs or their viability. In addition, the amount of extracted DNA was decreased in the frozen buffy coat that was stored for more than 7 days, though the DNA quality was acceptable. Conclusion: DNA should be extracted from fresh buffy coat samples as soon as possible after collection, especially for very important samples. Retaining the upper 40% of the cell pack of blood instead of whole blood could improve the storage efficiency of biobanking such samples. Our study provides a recommended option for blood collection and processing protocols in biobanking.
    Biopreservation and Biobanking 02/2015; 13(1):13-19.
  • Biopreservation and Biobanking 02/2015; 13(1):2-3.
  • Biopreservation and Biobanking 02/2015; 13(1):67-68.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Biobanks are important resources and central tools for translational medicine, which brings scientific research outcomes to clinical practice. The key purpose of biobanking in translational medicine and other medical research is to provide biological samples that are integrated with clinical information. In 2008, the Shanghai Municipal Government launched the "Shanghai Tissue Bank" in an effort to promote research in translational medicine. Now a sharing service platform has been constructed to integrate clinical practice and biological information that can be used in diverse medical and pharmaceutical research studies. The platform collects two kinds of data: sample data and clinical data. The sample data are obtained from the hospital biobank management system, and mainly include the donors' age, gender, marital status, sample source, sample type, collection time, deposit time, and storage method. The clinical data are collected from the "Hospital-Link" system (a medical information sharing system that connects 23 tertiary hospitals in Shanghai). The main contents include donors' corresponding medication information, test reports, inspection reports, and hospital information. As of the end of September 2014, the project has a collection of 16,020 donors and 148,282 samples, which were obtained from 12 medical institutions, and automatically acquired donors' corresponding clinical data from the "Hospital-Link" system for 6830 occurrences. This project will contribute to scientific research at medical institutions in Shanghai, and will also support the development of the biopharmaceutical industry. In this article, we will describe the significance, the construction phases, the application prospects, and benefits of the sample repository and information sharing service platform.
    Biopreservation and Biobanking 02/2015; 13(1):37-42.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Traditional nucleic acids preservation methods rely on maintaining samples in cold environments, which are costly to operate and time sensitive. Recent work validated that using room temperature for the storage of nucleic acids is possible if the samples are completely protected from water and oxygen. Here, we conducted accelerated aging and real-time degradation studies to evaluate the new technology DNAshell and RNAshell, which preserves DNA and RNA at room temperature, including the DNA and RNA yield, purity, and integrity. DNA and RNA solutions are dried in the presence of stabilizers in stainless steel minicapsules, then redissolved after different time points of heating and storing at room temperature. Results show that DNAshell and RNAshell ensure the safe storage of nucleic acids at room temperature for long periods of time, and that the quality of these nucleic acids is suitable for common downstream analysis.
    Biopreservation and Biobanking 02/2015; 13(1):49-55.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Ethical Management Guidelines for the Shanghai Disease-Based Biobank Network are intended to safeguard the interests of all the participants, to standardize the construction, management, and resource sharing of the Shanghai Disease-based Biobank Network, to promote the development of medical research, and to improve public health and well-being. The guidelines contain seven chapters: General Principles; Informed Consent; Use of Bio-samples from Persons without the Capacity to Consent; Privacy and Confidentiality; Applications of Use of Biological Samples and Data; Intellectual Property and Resource Sharing; and Conflict of Interest.
    Biopreservation and Biobanking 02/2015; 13(1):8-12.
  • Biopreservation and Biobanking 02/2015; 13(1):1.
  • [Show abstract] [Hide abstract]
    ABSTRACT: It is particularly necessary for biomedical researchers to obtain applicable biosamples accurately and efficiently, especially from a biobank with multiple-disease catalogs. To optimize the retrieval procedure, especially in the early stages of a non-automatic biobank, we developed a procedure that combined the electronic information system with a graphically designed printed recording system, which assisted in retrieving the samples quickly in a visualized way. In this procedure, we designed tables depending on the structure of equipment and registered the corresponding information in the tables layer by layer. Different samples from different types of diseases were first registered in the electronic system with the specific pre-allocation and barcodes. Then they were stored in the allocated position using their respective barcodes. In this way, the sample number and the location information in the electronic database were completely matched with the printed record. When the samples are needed, it is convenient to check the electronic information with the printed record. This procedure provides a convenient way to record the sample information during its lifecycle, and helps the administrator to double check information about the sample. The current solution offers an easy way for the transformation of a non-automatic biobank from the small-scale early-stage to the large-scale highly-automated level.
    Biopreservation and Biobanking 02/2015; 13(1):61-66.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human blood specimens serve as important research materials in the field of translational medicine research. The RNA extracted from blood, for example, represents the gene expression profiles of individuals or groups, and can be indicative of the pathological basis for human diseases. Meanwhile, the RNA quality may have severe impacts on the results of RNA studies. RNA is susceptible to many factors, such as the time of sample collection, transportation conditions, protectants, pretreatments, and extraction methods. In this study, six different pretreatment methods are evaluated for their effects on blood RNA extraction including the RNA yields and quality. Results show that most of these methods meet the basic requirements for RNA studies. While considering the simplicity of the procedure, the cost factor, and how to make full use of the samples, the proper method should be employed by researchers who have specific requirements for their research.
    Biopreservation and Biobanking 02/2015; 13(1):56-60.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: A novel frozen sample aliquotter, which consists of a drilling system in which a coring probe extracts multiple frozen cores from one frozen sample, was developed to avoid thawing and refreezing of samples. The aliquotter was tested to determine if it is suitable for metabolomics analyses in reproducibility and variability studies. Method: Twenty volunteers (10 males and 10 females) were enrolled in this study. Each of the volunteers' serum was aliquotted to one 1.8 mL tube and one 150 μL tube (control). Then the serum was frozen at -80°C for 2 weeks. Four frozen cores were taken from the perimeter of each of the 1.8 mL parent tubes by the aliquotter. The cores, the frozen serum remaining in the parent samples after extracting four frozen cores (Remainder), and control were analyzed using a gas chromatography time-of-flight mass spectrometry platform to test the reproducibility and variability of the samples in metabolomics analyses. Result: There were no significant differences between the Core, Remainder, and Control groups based on multivariate analysis of metabolomics analyses. In the reproducibility study, the average CV for the cores was 10.07%. In the variability study, the average changes ranged from 81.07% to 119.82% and 81.06% to 119.74% for Core and Remainder samples compared to Control, respectively. Conclusion: The frozen sample aliquotter technology can extract multiple consistently homogenous aliquots without thawing the parent sample, and the coring process with serum produces good samples for metabolomics analyses.
    Biopreservation and Biobanking 02/2015; 13(1):20-24.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Due to the requirement for comprehensive clinical research efforts in China, the importance of biobanking in modern clinical research is outlined in this overview. Hospitals, universities, and research institutes have been well organized as fundamental resources for Chinese biobanking initiatives and the resulting bio-sample collections. Here, a brief history and time line of development of biobanking in China will be introduced, as well as strategic designs for future biobanking development.
    Biopreservation and Biobanking 02/2015; 13(1):4-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is a growing interest in integrating biomaterial repositories into larger infrastructures in order to meet research demands. However, even for a single hospital or institute, where both population-based and multiple disease-based biobanks have existed for a long time, the integration of existing separate biobanks into a virtual cancer biobank is still challenging. The guidelines and procedures for biobanking are varied and not universally enforced or followed in separate biobanks. Within the last 2 years, we initiated a project to establish a centralized biobank facility in a common storage environment. Analyzing the challenges and interests of stakeholders for the biobanks, a working group comprised of representatives from the central and separate banks, ethic committees, and research administration offices reached an agreement to implement a central facility by following the ISBER best practices for biobanking, and including regular project reviews by the ethical and scientific boards. Furthermore, by implementing a modified minimum information system with biobank data sharing, a network based intra-hospital virtual cancer bank was established to facilitate sharing information of samples held by separate banks. Meanwhile, this virtual biobank network, which has integrated patient information from hospital health care systems, will gradually integrate follow-up information from the cancer registry office and data from epidemiology studies, providing controlled access for sample providers and resource users. In the future, this infrastructure designed for a single hospital may be helpful for building a broader virtual network for data and specimen exchanges.
    Biopreservation and Biobanking 02/2015; 13(1):43-48.
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article addresses the important issue of the standardization of the biobank process. It reports on i) the implementation of standard operating procedures for the processing of liquid-based cervical cells, ii) the standardization of storage conditions, and iii) the ultimate establishment of nationwide standardized biorepositories for cervical specimens. Given the differences in the infrastructure and healthcare systems of various county councils in Sweden, these efforts were designed to develop standardized methods of biobanking across the nation. The standardization of cervical sample processing and biobanking is an important and widely acknowledged issue. Efforts to address these concerns will facilitate better patient care and improve research based on retrospective and prospective collections of patient samples and cohorts. The successful nationalization of the Cervical Cytology Biobank in Sweden is based on three vital issues: i) the flexibility of the system to adapt to other regional systems, ii) the development of the system based on national collaboration between the university and the county councils, and iii) stable governmental financing by the provider, the Biobanking and Molecular Resource Infrastructure of Sweden (BBMRI.se). We will share our experiences with biorepository communities to promote understanding of and advances in opportunities to establish a nationalized biobank which covers the healthcare of the entire nation.
    Biopreservation and Biobanking 01/2015;
  • Biopreservation and Biobanking 01/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Stable dry-state storage of DNA is desirable to minimize required storage space and to reduce electrical and shipping costs. DNA purified from various commercially available dry-state stabilization matrices has been used successfully in downstream molecular applications (e.g., quantitative polymerase chain reaction [qPCR], microarray, and sequence-based genotyping). However, standard DNA storage conditions still include freezing of DNA eluted in aqueous buffers or nuclease-free water. Broad implementation of dry-state, long-term DNA storage requires enhancement of such dry-state DNA stabilization products to control for temperature fluctuations at specimen collection, transit, and storage. This study tested the integrity of genomic DNA subjected to long-term storage on GenTegra(™) DNA stabilization matrices (GenTegra LLC, Pleasanton, CA) at extreme conditions, as defined by a 4-year storage period at ambient temperature with an initial incubation for 7 months at 37°C, 56°C, or ambient temperature. Subsequently, purified DNA performance and integrity were measured by qPCR and next-generation sequencing (NGS)-based human leokocyte antigen (HLA) genotyping. High molecular weight genomic DNA samples were recovered from the GenTegra product matrix and exhibited integrity comparable to a highly characterized commercial standard under assessment by qPCR. Samples were genotyped for classical HLA loci using next generation sequencing-based methodolgy on the Roche 454 GS Junior instrument. Amplification efficiency, sequence coverage, and sequence quality were all comparable with those produced from a cell line DNA sequenced as a control. No significant differences were observed in the mean, median, or mode quality scores between samples and controls (p≥0.4). Next generation HLA genotyping was chosen to test the integrity of GenTegra-treated genomic DNA due to the requirment for long sequence reads to genotype the highly polymorphic classical HLA genes. Experimental results demonstrate the efficacy of the GenTegra product as a suitable genomic DNA preservation tool for collection and long-term biobanking of DNA at fluctuating and high temperatures.
    Biopreservation and Biobanking 12/2014; 12(6):402-8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Biobank-suisse (BBS) is a collaborative network of biobanks in Switzerland. Since 2005, the network has worked with biobank managers towards a Swiss biobanking platform that harmonizes structures and procedures. The work with biobank managers has shown that long-term, sustainable financing is difficult to obtain. In this report, three typical biobank business models are identified and their characteristics analyzed. Five forces analysis was used to understand the competitive environment of biobanks. Data provided by OECD was used for financial estimations. The model was constructed using the business model canvas tool. The business models identified feature financing influenced by the economic situation and the research budgets in a given country. Overall, the competitive environment for biobanks is positive. The bargaining power with the buyer is negative since price setting and demand prediction is difficult. In Switzerland, the healthcare industry collects approximately 5600 U.S. dollars per person and year. If each Swiss citizen paid 0.1% (or 5 U.S. dollars) of this amount to Swiss biobanks, 45 million U.S. dollars could be collected. This compares to the approximately 10 million U.S. dollars made available for cohort studies, longitudinal studies, and pathology biobanks through science funding. With the same approach, Germany, the United States, Canada, France, and the United Kingdom could collect 361, 2634, 154, 264, and 221 million U.S. dollars, respectively. In Switzerland and in other countries, an annual fee less than 5 U.S. dollars per person is sufficient to provide biobanks with sustainable financing. This inspired us to construct a business model that not only includes the academic and industrial research sectors as customer segment, but also includes the population. The revenues would be collected as fees by the healthcare system. In Italy and Germany, a small share of healthcare spending is already used to finance selected clinical trials. The legal frameworks could serve as templates for the business model proposed here.
    Biopreservation and Biobanking 12/2014; 12(6):389-94.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The current study investigates whether access arrangements relevant for biobanking contain clear information on key access conditions. It furthermore assesses the extent to which these access conditions are harmonized across biobank initiatives. A comparative analysis was conducted of access arrangements developed by 26 organizations, 36 biobank networks, and 20 biobanks worldwide. The study demonstrates a lack of clear information on 21 key access conditions relevant for biobanking. Furthermore, it confirms that the harmonization across biobank initiatives is limited. Many biobank initiatives need to be more transparent on how they apply the studied access conditions.
    Biopreservation and Biobanking 12/2014; 12(6):415-22.